Recombinant Human SLAM/CD150 Protein, CF

Catalog #: 164-SL Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
164-SL-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human SLAM/CD150 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. Recombinant Human SLAM/CD150 binds to Biotinylated Recombinant Human SLAM/CD150 with an ED50 of 0.0400-0.400 μg/mL.

Source

Mouse myeloma cell line, NS0-derived human SLAM/CD150 protein
Ala21-Lys236 with a C-terminal 6-His tag

Accession #

Q13291

N-terminal Sequence
Analysis

Ala21 & Thr25

Predicted Molecular Mass

25 kDa

SDS-PAGE

40-65 kDa, reducing conditions

Product Datasheets

164-SL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

164-SL

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 250 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: SLAM/CD150

The type I transmembrane glycoprotein Signaling Lymphocytic Activation Molecule (SLAM), also known as CD150, is the prototypic member of the SLAM subfamily of the CD2 protein family. CD2 family proteins function as adhesion molecules and modulators of the immune response (1). Mature human SLAM consists of a 217 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 77 aa cytoplasmic domain with three immunoreceptor tyrosine switch motifs (ITSM) (2). Within the ECD, human SLAM shares 58% and 56% aa sequence identity with mouse and rat SLAM, respectively. Alternative splicing generates two additional isoforms, with one showing a deletion in the cytoplasmic region (aa 299-335), and a second showing a deletion in the transmembrane domain (aa 234-263). It is expressed as a 75 kDa molecule, of which approximately 30 kDa represents N-linked carbohydrate (3). SLAM is expressed on T cells, B cells, thymocytes, macrophages, dendritic cells, platelets, and hematopoietic stem cells, and it is up-regulated on activated B cells and CD4⁺ and CD8⁺ T cells (2‑8). SLAM interacts homophilically with low affinity, and this interaction induces a Th0/Th1 phenotype in CD8⁺ T cells that is characterized by clonal expansion, production of IFN-gamma, and increased cytolytic activity (2, 3, 9-11). In addition, this interaction on CD4⁺ T cells promotes a Th2-type response, likely due to an association with the adaptor molecule SAP (4, 12). SLAM ligation also promotes an allergen-induced eosinophil and mast cell activation, NKT cell development, and the microbicidal response of macrophages to Gram negative bacteria (8, 13-15). In humans, SLAM functions as a cellular entry receptor for measles virus (16, 17).

References

Cannons, J.L. et al. (2011) Annu. Rev. Immunol. 29:665.
Cocks, B.G. et al. (1995) Nature 376:260.
Castro, A.G. et al. (1999) J. Immunol. 163:5860.
Wang, N. et al. (2004) J. Exp. Med. 199:1255.
Hahm, B. et al. (2004) Virology 323:292.
Nanda, N. et al. (2005) Blood 106:3028.
Kiel, M.J. et al. (2005) Cell 121:1109.
Punnonen, J. et al. (1997) J. Exp. Med. 185:993.
Mavaddat, N. et al. (2000) J. Biol. Chem. 275:28100.
Aversa, G. et al. (1997) J. Immunol. 158:4036.
Mehrle, S. et al. (2008) Mol. Immunol. 45:796.
Davidson, D. et al. (2004) Immunity 21:707.
Wang, N. et al. (2006) Am. J. Respir. Cell Mol. Biol. 35:206.
Jordan, M.A. et al. (2011) J. Immunol. 186:3953.
Berger, S.B. et al. (2010) Nat. Immunol. 11:920.
Tatsuo, H. et al. (2000) Nature 406:893.
Hsu, E.C. et al. (2001) Virology 279:9.

Long Name

Signaling Lymphocytic Activation Molecule

Entrez Gene IDs

6504 (Human); 27218 (Mouse); 102135470 (Cynomolgus Monkey)

Alternate Names

CD 150; CD150; CD150IPO-3; CDw150; IPO-3; signaling lymphocytic activation molecule family member 1; signaling lymphocytic activation molecule; SLAM; SLAMCD150 antigen; SLAMF1